DV Trading LLC Takes $1.53 Million Position in SAB Biotherapeutics, Inc. $SABS

Key Points

• DV Trading LLC acquired 400,000 shares of SAB Biotherapeutics during the first quarter, valued at approximately $1.53 million and representing about 0.52% of the company. Institutional investors and hedge funds collectively own 7.82% of SABS.
• Analysts remain broadly positive, with nine Buy ratings, one Hold, and one Sell; the consensus rating is “Moderate Buy” with an average price target of $12, well above the stock’s $3.57 opening price.
• SABS recently traded between $1.85 and $5.15 over the past year and reported a quarterly loss of $0.35 per share, missing estimates of a $0.20 loss. Analysts expect a full-year loss of approximately $1.19 per share.

DV Trading LLC purchased a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 400,000 shares of the company's stock, valued at approximately $1,532,000. DV Trading LLC owned about 0.52% of SAB Biotherapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. bought a new position in SAB Biotherapeutics in the first quarter valued at approximately $29,000. ADAR1 Capital Management LLC acquired a new stake in shares of SAB Biotherapeutics during the third quarter worth $30,000. Dimensional Fund Advisors LP bought a new stake in SAB Biotherapeutics in the third quarter valued at about $32,000. State of Wyoming bought a new stake in SAB Biotherapeutics in the fourth quarter valued at about $34,000. Finally, Virtu Financial LLC acquired a new position in SAB Biotherapeutics in the third quarter valued at about $40,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SABS has been the topic of a number of recent analyst reports. Leerink Partners raised their target price on SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an "outperform" rating in a report on Monday, June 15th. Jefferies Financial Group initiated coverage on SAB Biotherapeutics in a research note on Wednesday, May 20th. They issued a "buy" rating and a $11.00 price target for the company. Rodman & Renshaw reiterated a "buy" rating and issued a $13.00 price target on shares of SAB Biotherapeutics in a research report on Monday, May 11th. Barclays assumed coverage on shares of SAB Biotherapeutics in a research note on Wednesday, June 24th. They set an "overweight" rating and a $13.00 price objective on the stock. Finally, Chardan Capital boosted their price objective on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the company a "buy" rating in a report on Wednesday, June 17th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $12.00.

SAB Biotherapeutics Price Performance

Shares of SABS opened at $3.57 on Friday. The stock has a 50 day simple moving average of $3.67 and a 200 day simple moving average of $3.83. SAB Biotherapeutics, Inc. has a 52-week low of $1.85 and a 52-week high of $5.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. The firm has a market capitalization of $272.96 million, a PE ratio of -1.69 and a beta of 0.52.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Sell-side analysts predict that SAB Biotherapeutics, Inc. will post -1.19 EPS for the current fiscal year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.